

Maciej Matusiak

Maciej Matusiak studied at the Technical University of Lodz in Lodz from 1986 to 1992.

In 1994 he obtained a securities broker's license (no. 1203); issued by the Securities Commission (now the FSC). In 2002, he received the title of Chartered Financial Analyst (granted by the CFA Institute, Charlottesville, VA, USA). In addition, he has completed a number of training courses in financial analysis, investment consulting, and asset management.

He has very extensive experience in supervising companies listed on the Warsaw Stock Exchange as an independent member of Supervisory Boards, including as chairman/member of Audit Committees.

In the period 07.1995-05.1996 he worked at Daewoo Towarzystwo Ubezpieczeniowe S.A. (Management Office), Warsaw, Department of Capital Investments as a securities dealer, financial analyst. In the period 05.1996-04.1998 he worked at Bank Brokerage House PKO-BP, Warsaw. Asset Management Department as a financial analyst. From 04.1998 to 04.2002 he worked at Commercial Union Polska - Towarzystwo Ubezpieczeń na Życie S.A., Warsaw, Department Investments and at Commercial Union Investment Management (Polska) S.A., Warsaw, Asset Management Department - senior equity analyst.

In the period of 03.2006-11.2013 he was a partner and served as President of the Management Board of Artemis Investment Sp. z o.o., Warsaw.

In the past, he was a member of the supervisory boards of many public companies listed on the WSE SA, including: Grupa KĘTY S.A. (Kęty), LPP S.A. (Gdańsk), Wandalex S.A. (Warsaw), Elstar Oils S.A. (Elbląg), K2 Internet S.A. (Warsaw), TIM S.A. (Wrocław), Interbud-Lublin

S.A. (Lublin), Vistula Group S.A. (Kraków), Libet S.A. (Wrocław), MLP Group S.A. (Pruszków).

He is currently a member of supervisory boards and member/chairman of Audit Committees at: BBI Development S.A. (Warsaw), ZPC Otmuchów S.A. (Otmuchów), Atende S.A. (Warsaw), Krakchemia S.A. (Kraków), BEST S.A. (Gdynia), Urteste S.A. (Gdańsk), ESALIENS Towarzystwo Funduszy Inwestycyjnych S.A. (Warsaw), Mex Polska S.A. (Lodz).

Mr. Maciej Matusiak is not engaged in any activities competitive to Urteste S.A., does not participate in a competitive company as a partner in a civil partnership, a partnership, is not a member of a body of a competitive capital company, and does not participate in any other competitive legal entity as a member of its body.

Mr. Maciej Matusiak is not registered in the Register of Insolvent Debtors, maintained pursuant to the Act on the National Court Register.

Jaroslav Biliński

Jaroslav Biliński holds a university degree and a doctorate in medical sciences and health sciences. He graduated from the Medical College of the Nicolaus Copernicus University. In 2013, he was licensed to practice medicine. In 2017, he received a doctorate in medical sciences, and in 2024 he received a postdoctoral degree.

n. med. and n. o zdr. at the Warsaw Medical University. He has gained professional experience: (i) as a physician since 2013, (ii) as an assistant at Warsaw Medical University from 2018 until now, (iii) as Vice President of the District Medical Chamber of Warsaw from 2018-2020, (iv) as President and Partner of Human Biome Institute S.A. since 2020.

Winner of the prestigious Faculty Award of the Fifth Faculty of Medicine of the Polish Academy of Sciences. In 2020, elected "Young Ambassador of the European Society for Blood and Marrow Transplantation (EBMT) and winner of the "Golden OTIS" competition in the category of

"scientific debut of the year". His scientific work includes topics in the fields of hematology, clinical transplantation, immunology, antibiotic resistance, metagenomics, genetics and anti-tumor response, the gut microbiome and its interactions with the host.

He has authored numerous full-text publications in prestigious scientific journals, post-conference abstracts and conference reports, including those at prestigious international congresses.

Mr. Jaroslav Biliński is not engaged in any activities competitive to Urteste S.A., does not participate in a competitive company as a partner in a civil partnership, partnership, is not a member of a body of a competitive capital company, and does not participate in any other competitive legal person as a member of its body.

Mr. Jaroslav Biliński is not registered in the Register of Insolvent Debtors, maintained pursuant to the National Court Register Act.

Magdalena Wysocka

Magdalena Wysocka Magdalena Wysocka holds a university degree and a doctoral degree in chemical sciences. She is a professor at the University of Gdansk in the Department of Biomedical Chemistry of the Faculty of Chemistry. her achievements include 162 publications cited more than 1,800 times, total IF 231, index h=19 and two patents.

Ms. Magdalena Wysocka is not engaged in any activities competitive to Urteste S.A., does not participate in a competitive company as a partner in a civil partnership, partnership, is not a member of a body of a competitive capital company, and does not participate in any other competitive legal entity as a member of its body.

Ms. Magdalena Wysocka is not registered in the Register of Insolvent Debtors, maintained pursuant to the Act on the National Court Register.

Slawomir Kościak

Slawomir Kościak holds a university degree. In 2009, he graduated with a degree in finance and banking from the Warsaw School of Economics and obtained a CEMS Master in International Management from the University of Cologne. In 2010, he was certified as an investment advisor, and in 2015 he obtained the Chartered Financial Analyst (CFA) title. He gained professional experience: (i) in 2007 at the European Investment Fund in Luxembourg as an analyst, (ii) in 2008 at the real estate fund Morgan Stanley Real Investment GmbH in Frankfurt as an analyst, (iii) from 2009 to 2020 managed a number of funds and investment strategies within the Investment Fund Company PZU S.A., including as an analyst, portfolio manager, member of the Investment Committee, and since 2014 as Medical Sector Director (iv) from February 2021 to June 2024 as a member of the Supervisory Board, Audit Committee, and Nomination and Remuneration Committee at Mabion S.A, (v) from July 2022 to June 2024 as a member of the Supervisory Board and the Nomination and Remuneration Committee at Medicalgorithmics S.A., (vi) from November 2022 as a member of the Supervisory Board at Auxilius Pharma sp. z o.o., (vii) from September 2023 as a member of the Supervisory Board of MediSensonic S.A., (viii) from March 2025 as Chief Financial Officer at Biotechna S.A.. Since July 2023, Slawomir Kościak has also been a member of the Association of Independent Supervisory Board Members.

Mr. Slawomir Kościak is not engaged in any activities competitive to Urteste S.A., does not participate in a competitive company as a partner in a partnership, is not a member of a body of a competitive capital company, and does not participate in any other competitive legal person as a member of its body.

Mr. Slawomir Kościak is not registered in the Register of Insolvent Debtors, maintained pursuant to the Act on the National Court Register.

Grzegorz Basak

Prof. Grzegorz Basak, MD, is a physician, specialist in internal medicine, hematology and clinical transplantology. Since 2018, he has served as head of the Department of Hematology, Transplantology and Internal Medicine at the University Clinical Center of the Medical University of Warsaw. His main research interests are in the field of cellular therapies, with a special focus on CAR-T lymphocytes. Creator and P.I. of the first Polish non-commercial clinical trial with locally produced CAR-T antiCD19 lymphocytes.

Graduated with honors from the Medical University of Warsaw in 2003, and received his PhD in 2005 based on his research on experimental cancer immunotherapy. He held postdoctoral fellowships at Temple University (2003, Philadelphia, USA) and the University of California, San Diego (2007- 2008) in experimental hematology and stem cell research.

Winner of several competitions, including the START grant from the Foundation for Polish Science, the scholarship from the Ministry of Science and Higher Education for outstanding young scientists (2012-2015), the "Supertalents in Medicine 2016" Puld of Medicine, "Scientist of the Future 2022" awards. (Center for Intelligent Development), "Wprost Innovators 2022". Graduate of the Ministry of Science and Higher Education's Top500 Innovators program in research management and commercialization (Cambridge and Oxford, UK, 2015). Member of the Council of Young Scientists at the Ministry of Science and Higher Education (2012-2013). Secretary of the Working Group on Complications and Quality of Life (2011-2017) and Chairman of the Working Group on Transplant Complications of the European Society for Blood and Marrow Transplantation (EBMT, 2017-2021), member of the EBMT Scientific Council (2017-2021). Member of the Scientific Council of the Institute of Hematology and Transfusiology (Poland, 2022-2024) and member of the Board of the Polish Society of Hematology and Transfusiology (PTHiT, since 2023). Currently, his main clinical and scientific interests are issues related to cell therapies (including CAR-T), artificial intelligence in medicine, and microbiome research. Co-author of > 290 international publications with a total IF > 1000, >4700 citations and Hirsch index of 37. Co-founder of Saventic Health Sp. z o. o. engaged in innovative solutions of artificial intelligence in rare disease diagnostics and Human Biome Institute - a company focused on innovative microbiome-based therapies.

Mr. Grzegorz Basak does not conduct any activity competitive to Urteste S.A., does not participate in a competitive company as a partner in a civil partnership, partnership, is not a member of a body of a competitive capital company, and does not participate in any other competitive legal person as a member of its body.

Mr. Grzegorz Basak is not registered in the Register of Insolvent Debtors, maintained pursuant to the Act on the National Court Register.